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Letter to the Editor
Cholangiocarcinoma is a dismal tumor, difﬁ  cult to treat and in the majority of cases surgery is the 
only available method of cure, however only in early stages.
1 In advanced cases (turmors Klatskin 
III and IV) palliative therapy with endoscopic drainage of bile ducts is the only effective and accept-
able method of treatment.
2 Adjuvant palliative therapies either with radiotherapy or chemotherapy 
in order to stabilize the disease gave controversial results and in some aspect unacceptable.
1–2 The 
need for new treatment to stabilize the disease, increase survival with acceptable quality of life is 
urgent.
Somatostatin and its long-acting analogues have been successfully used in symptom control in 
patients with advanced neuroendocrine gastrointestinal tumours.
3,4 Moreover, octreotide, a somatostatin 
analogue, showed signiﬁ  cant efﬁ  cacy for the management of hepatocellular carcinoma in many studies 
and reviews.
5 Pistevou-Gombaki et al.
6,7 also reported a positive experience in liver metastases from 
non-neuroendocrine tumors with the use of octreotide LAR.
A possible antitumor mechanism of octreotide is a stimulatory effect on Kupffer cells, induction of 
apoptosis or other antiproliferative actions, inhibition of proliferation, which have been suggested but 
not proved.
3,4
The aim of the present study is to evaluate the role, if any, of octreotide in palliative treatment of 
end-stage, inoperable, cholangiocarcinomas (Klatskin III and IV tumors), taking into account the above-
mentioned positive experience in relation to the absence of clear data and efﬁ  cacy of any available 
treatments in end-stage cholangiocarcinomas.
We report on two male patients (A, B) 63- and 81- years-old, with obstructive icterus, due to advanced 
cholangiocarcinoma stage Klatskin III and IV respectively and liver metastases in patient A, who were 
palliatively treated by long acting octreotide IM (octreotide LAR) monthly, according to schema 
published previously,
7 in combination with successful endoscopic bile duct drainage.
In both patients Klatskin tumor was demonstrated, in ﬁ  rst instance by abdominal echosonography 
and computed-tomography (CT), and thereafter by magnetic resonance imaging (MRI) and magnetic 
retrograde cholangiopancreatography (MRCP). Operation was excluded either due to advanced disease 
in patient A (liver metastases) and due to advanced age in patient B (81 years-old). Liver transplantation 
was also excluded due to advanced age and disease.
Clinical examination revealed severe liver mass in both patients. Laboratory examination showed 
high bilirubin levels up to 30 mg/dl direct 20 mg/dl indirect 10 mg/dl, increased γ-GT, SGPT, ALF and 
highly increased tumor markers (CEA 1000 and CA19–9 1000 mg/dl) in both patients. CRP was 
also elevated in both patients without however any other signs of overt cholangitis. In MRCP gallbladder 
was excluded in both patients due to inﬁ  ltration of cystic duct by the tumor.
According to clinicolaboratoty results of these cases, the patients were urgently treated by ERCP, 
schicterotomy and successful metallic stent placement in order to drain the bile ducts. Both patients 368
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were discharged and bilirubin normalized in a few 
days. Radiotherapy or chemotherapy was refused 
from both patients after having explained the risk-
beneﬁ  t ratio. The patients complained for general 
symptoms attributed to Klatksin tumors, including 
right upper abdominal pain, loss of appetite, mal-
aise and weight loss.
At ﬁ  rst instance all patients were under sup-
portive therapy with common analgesics and 
enteral nutrition, upon indication, with mild 
improvement of right upper abdominal pain. A 
month after metallic stent placement and success-
ful bile duct drainage, the right upper abdominal 
pain, attributed to liver tumor, deteriorated and 
produced severe morbidity, which was not respond-
ing to further increase of analgesics. Laboratory 
examination showed normal bilirubin levels, which 
remained normal during follow-up six months after 
stent placement.
At that time and in combination with the 
absence of clear data to support any beneﬁ  t from 
any therapy in these debilitating patients, in order 
to stabilize the disease, it was decided to further 
treat the patients with 20 mg long acting octreotide 
IM (octreotide LAR), once the ﬁ  rst day, octreotide 
SC 0,5 mgX3/daily, days 2–14 and then 20 mg 
long acting octreotide IM montly, as in previous 
studies in patients with symptomatic liver 
metastases.
6,7
The follow-up was done with clinicolaboratory 
examination and abdominal ultrasonography 
before and at one-month intervals after the initia-
tion of octreotide therapy. The evaluation of the 
pain related to cholangiocarcinoma was performed 
at baseline and monthly after initiation of 
octreotide-treatment, using the visual analogue 
scale (VAS). The palliative effect was also assessed 
every month using the analgesic intake scale (AIS) 
according to WHO (0 = no analgesics; 1 = NSAID; 
2 = weak opioids; 3 = morphine).
One month after the administration of octreotide, 
the right upper abdominal pain was in general terms 
decreased. In fact, both patients reported moderate 
to excellent subjective improvement with 3 and 4 
points decrease of VAS score in patient A and B 
respectively. An interesting point of the study was 
that, the local pain at the right upper abdomen 
relapsed when octreotide was temporarily stopped 
or at the end of every month just before the next 
injection of octreotide LAR and reduced again soon 
after the initiation of octreotide. Furthermore, one 
month after octreotide was started the AIS was 
signiﬁ  cantly reduced (from 3 to one in patient A 
and from 3 to 2 and then to one in patient B) and 
remained in these levels during the six-months 
follow-up.
As far as the side effects are concerned octreo-
tide was generally well-tolerated. Slight hypergly-
cemia was reported in both patients treated by 
speciﬁ  c diet. No other severe side effects due to 
octreotide-treatment were reported.
During follow-up, six months after the initiation 
of octreotide therapy, both patients were in good 
general condition, local pain improvement was still 
reported, no analgesics were necessary and both 
patients were still alive without icterus. Although 
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Figure 1. Time course of VAS and AIS values in pt A after octreotide administration.369
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endoscopic metallic stent placement was successful 
for bile duct drainage, abdominal pain attributed 
to tumor growth persisted and even increased, soon 
after stent placement. In view of this evolution, we 
decided to further treat the patients with octreotide 
LAR, which resulted in good pain control and 
reduce of analgesics. The most important is that 
the values of VAS and AIS remained stable after 
the ﬁ  rst month of improvement, as it is shown in 
Figures 1 and 2. Kapadia commenting on the 
improvement of quality of life after the administra-
tion of octreotide in patients with hepatocellular 
carcinoma, reported that the possible mechanism 
of this should be the diminishing of the effects of 
various humoral agents and/or cytokines released 
from the tumor.
8
To our knowledge this is the ﬁ  rst study of the 
palliative use of octreotide in end-stage cholangio-
carcinoma, although the inhibitory effects of 
octreotide on cholangiocarcinoma cell lines have 
been investigated in vitro and in vivo with positive 
results.
9 Zhao B et al.
9 reported that octreotide 
inhibits the proliferation of cholangiocarcinoma 
cells through G0/G1 cell cycle arrest. It seems that 
a potential new therapeutic approach for cholan-
giocarcinoma has been investigated in the present 
study. However, we did not have control group and 
the small number of patients made the evaluation 
of our results more difﬁ  cult.
We consider the use of octreotide potentially 
effective in disease stabilization and a good 
alternative in palliative treatment of end stage 
cholangiocarcinoma with minimum or absence of 
side effects. The positive results of the present 
study encourage further randomized controlled 
trials of octreotide in the treatment of end-stage 
cholangiocarcinomas.
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Figure 2. Time course of VAS and AIS values in pt B after octreotide administration.